About SYNEDGEN, INC.
Synedgen is a biotechnology company focused on developing first-in-class therapeutics that repair mucosal barriers and reduce inflammation, with a lead asset MIIST305 targeting gastrointestinal diseases and radiation injury.
Developing first-in-class therapeuticsPromoting mucosal and dermal barrier repairScalable GMP productionStrong IP positionModulating secondary immune signaling
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED | Department of Health and Human Services | $18.8M | |
| SBIR PHASE III PROPOSAL NO. JW230017 TITLED, "OPTIMIZED, FIELD-STABLE GLYCOPOLYMER-MIMICKING POLYSACCHARIDE TO | Department of Defense | $2.3M | |
| AWARD OF SYNEDGEN'S DHA SBIR PHASE III FOLLOW-ON MEDICAL R&D CONTRACT FOR "DEVELOPMENT OF TECHNOLOGIES THAT CO | Department of Defense | $550K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to SYNEDGEN, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.